3 Reasons To Buy Merck For The Long Term

Related MRK Pharma ETFs in Focus on String of Earnings Beat - ETF News And Commentary Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

Merck (NYSE: MRK) is a blue chip "Big Pharma" stock that is up for the last week, month, quarter, six months and year of market action.

For 2014, Merck has risen by nearly 19 percent. There are three reasons for long-term investors to buy shares of Merck in expectation that the share price will increase even more.

Merck Has A Solid Pipeline Of Products And Services

The bullish trajectory of its earnings is testament to that. Earnings per share for Merck for the last five years was a -16.50 percent. This year, it is even worse at a -26.50 percent.

Next year, however, earnings-per-share are expected to jump to 4.55 percent. For the next five years, earnings per share for Merck are expected to be at almost 4 percent.

Related: Reasons To Buy Cracker Barrel On The Dip

It's On A Bullish Trend

The dividend component of Merck also makes it appealing for long-term investors. At present, the dividend yield for a member of the Standard & Poor's 500 Index averages about 1.8 percent. The dividend yield for Merck is 3 percent, more than 50 percent higher. Income investors should also like that Merck is a Dividend Aristocrat. That means the company has increased its dividend yield annually for at least the last 25 years. From that, shareholders get a raise each year just for owning the stock.

Demographics Favor Merck

The world is getting older and richer. That change results in more spending on healthcare goods and services. From that, Merck will prosper.

Merck is now trading around $57.85. The mean analyst target price for the next year of market action is $60.94. Making the future look even more bullish is that Merck has a tiny short float, evincing that few expert the price to fall.

Posted-In: healthcare medicineLong Ideas Dividends Emerging Markets Technicals Markets Trading Ideas Best of Benzinga

© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  Most Popular Morgan Stanley: 'Prepare To Buy The Dip' On Tesla's Q2 Earnings Earnings Scheduled For July 30, 2014 Earnings Scheduled For July 31, 2014 NQ Mobile Soars On Offer From Bison Capital Wells Fargo Securities Sees Positive Catalysts Ahead For Apple BlackBerry Shares Move On Windows Phone Announcement Related Articles (SPY + MRK) 3 Reasons To Buy Merck For The Long Term Pharma ETFs in Focus on String of Earnings Beat - ETF News And Commentary The 3 Biggest ETFs In The World Reasons To Buy Cracker Barrel On The Dip Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties Pharmaceutical ETFs Are Health Care Sector Standouts Around the Web, We're Loving...